Correction to: “Is There Still a Role for Dual Antiplatelet Therapy in the Secondary Prevention of Lacunar Stroke?”

HomeStrokeVol. 54, No. 11Correction to: “Is There Still a Role for Dual Antiplatelet Therapy in the Secondary Prevention of Lacunar Stroke?” Free AccessCorrectionPDF/EPUBAboutView PDFView EPUBSections ToolsAdd to favoritesDownload citationsTrack citationsPermissions ShareShare onFacebookTwitterLinked InMendeleyReddit Jump toFree AccessCorrectionPDF/EPUBCorrection to: “Is There Still a Role for Dual Antiplatelet Therapy in the Secondary Prevention of Lacunar Stroke?” Originally published23 Oct 2023https://doi.org/10.1161/STR.0000000000000448Stroke. 2023;54:e493This article corrects the followingIs There Still a Role for Dual Antiplatelet Therapy in the Secondary Prevention of Lacunar Stroke?In the article by Shoamanesh, “Is There Still a Role for Dual Antiplatelet Therapy in the Secondary Prevention of Lacunar Stroke?” which published online on August 28, 2023 and appeared in the September 2023 issue Stroke (Stroke.2023;54:2251–2253. doi: 10.1161/STROKEAHA.123.043626), corrections are needed.It was stated: “The present observations are particularly interesting in light of similar results reported with long-term DAPT using cilostazol plus aspirin or clopidogrel versus single antiplatelet therapy in subgroup analyses of the CSPS.com trial (Cilostazol Stroke Prevention Study for Antiplatelet Combination) where Japanese patients with qualifying lacunar stroke (925; 49% of total trial population) within 8 to 18 days of symptom onset benefited from a 55% relative risk reduction in stroke recurrence without offsetting harm from bleeding with this particular DAPT regimen over an average treatment duration of 1.8 years.”The correct description should be “The present observations are particularly interesting in light of similar results reported with long-term DAPT using cilostazol plus aspirin or clopidogrel versus single antiplatelet therapy in subgroup analyses of the CSPS.com trial (Cilostazol Stroke Prevention Study for Antiplatelet Combination) where Japanese patients with qualifying lacunar stroke (925; 49% of total trial population) within 8 to 180 days of symptom onset benefited from a 55% relative risk reduction in stroke recurrence without offsetting harm from bleeding with this particular DAPT regimen over an average treatment duration of 1.8 years.”These corrections have been made to the current online version of the article, which is available at https://www.ahajournals.org/doi/10.1161/STROKEAHA.123.043626. eLetters(0) eLetters should relate to an article recently published in the journal and are not a forum for providing unpublished data. Comments are reviewed for appropriate use of tone and language. Comments are not peer-reviewed. Acceptable comments are posted to the journal website only. Comments are not published in an issue and are not indexed in PubMed. Comments should be no longer than 500 words and will only be posted online. References are limited to 10. Authors of the article cited in the comment will be invited to reply, as appropriate. Comments and feedback on AHA/ASA Scientific Statements and Guidelines should be directed to the AHA/ASA Manuscript Oversight Committee via its Correspondence page. Sign In to Submit a Response to This Article Previous Back to top Next FiguresReferencesRelatedDetailsRelated articlesIs There Still a Role for Dual Antiplatelet Therapy in the Secondary Prevention of Lacunar Stroke?Ashkan Shoamanesh,Stroke. 2023;54:2251-2253 November 2023Vol 54, Issue 11 Advertisement Article Information Metrics © 2023 American Heart Association, Inc.https://doi.org/10.1161/STR.0000000000000448PMID: 37871246 Originally publishedOctober 23, 2023 PDF download Advertisement